Symbols / CRVO $3.94 +1.29% CervoMed Inc.

Healthcare • Biotechnology • United States • NCM

CRVO Chart

O: — H: — L: — C: — V: —

SMA 20: — SMA 50: — SMA 200: —

About

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Fundamentals

Scroll to Statements

Market Cap	36.48M	Enterprise Value	15.15M	Income	-26.97M	Sales	4.01M	Book/sh	1.97	Cash/sh	2.25
Dividend Yield	—	Payout	0.00%	Employees	15	IPO	—	P/E	—	Forward P/E	-2.33
PEG	—	P/S	9.11	P/B	2.00	P/C	—	EV/EBITDA	—	EV/Sales	3.78
Quick Ratio	4.57	Current Ratio	4.91	Debt/Eq	—	LT Debt/Eq	—	EPS (ttm)	-2.98	EPS next Y	-1.69
EPS Growth	—	Revenue Growth	-99.60%	Earnings	2026-05-07	ROA	-53.62%	ROE	-93.92%	ROIC	—
Gross Margin	0.00%	Oper. Margin	-954.79%	Profit Margin	0.00%	Shs Outstand	9.26M	Shs Float	6.29M	Short Float	4.89%
Short Ratio	4.56	Short Interest	—	52W High	13.13	52W Low	3.51	Beta	-5.04	Avg Volume	79.49K
Volume	57.18K	Target Price	$22.14	Recom	Strong_buy	Prev Close	$3.89	Price	$3.94	Change	1.29%

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus

$22.14

Mean price target

2. Current target

$3.94

Latest analyst target

3. DCF / Fair value

$-25.88

Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …

Ratings

Current target

$3.94

Low

$11.00

High

$31.00

Mean

$22.14

Latest analyst rating changes

Date	Action	Analyst	Rating Change	Price Target
2026-04-22	main	D. Boral Capital	Buy → Buy	$31
2026-04-08	main	D. Boral Capital	Buy → Buy	$31
2026-03-19	main	D. Boral Capital	Buy → Buy	$31
2026-03-18	main	Roth Capital	Buy → Buy	$11
2026-03-18	main	Chardan Capital	Buy → Buy	$21
2026-03-16	main	D. Boral Capital	Buy → Buy	$31
2026-03-05	main	Chardan Capital	Buy → Buy	$15
2026-03-04	main	D. Boral Capital	Buy → Buy	$31
2026-02-18	main	D. Boral Capital	Buy → Buy	$31
2025-12-18	init	Cantor Fitzgerald	— → Overweight	—
2025-12-18	reit	HC Wainwright & Co.	Buy → Buy	$25
2025-12-05	main	D. Boral Capital	Buy → Buy	$31
2025-12-02	main	D. Boral Capital	Buy → Buy	$31
2025-11-11	main	D. Boral Capital	Buy → Buy	$31
2025-11-05	up	HC Wainwright & Co.	Neutral → Buy	$25
2025-11-04	main	D. Boral Capital	Buy → Buy	$31
2025-09-08	reit	HC Wainwright & Co.	Neutral → Neutral	$11
2025-08-18	main	D. Boral Capital	Buy → Buy	$31
2025-08-12	reit	Roth Capital	Buy → Buy	$16
2025-08-11	main	Chardan Capital	Buy → Buy	$15

News

RSS: Latest CRVO news

Drug candidate boosted brain region tied to Lewy body dementia - Stock Titan Wed, 22 Apr 2026 11
CRVO (CervoMed Inc.) reports wider-than-expected Q4 2025 loss driven by elevated clinical research spending. - Decline Phase - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 20
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results - TipRanks Wed, 22 Apr 2026 20
CervoMed (CRVO) Shows Promise in DLB Treatment with Neflamapimod - GuruFocus Wed, 22 Apr 2026 15
$CRVO stock is down 11% today. Here's what we see in our data. - Quiver Quantitative ue, 02 Dec 2025 08
Is CervoMed (CRVO) stock a good candidate for diversification (Investor Concern) 2026-04-18 - Community Pattern Alerts - Xã Châu Thành Sat, 18 Apr 2026 22
CervoMed (NASDAQ:CRVO) Will Have To Spend Its Cash Wisely - simplywall.st Wed, 18 Feb 2026 08
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Fri, 07 Nov 2025 08
$CRVO stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Mon, 17 Nov 2025 08
A blood test flagged which Lewy body dementia patients benefited more - Stock Titan hu, 19 Mar 2026 07
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance Fri, 13 Mar 2026 07
CervoMed (CRVO) Maintains "Buy" Rating with $31 Price Target | C - GuruFocus Wed, 08 Apr 2026 13
CervoMed picks 50mg dose for dementia drug after Phase 1 study - Stock Titan Wed, 04 Mar 2026 08
Chardan Capital Maintains Buy Rating for CRVO | CRVO Stock News - GuruFocus hu, 05 Mar 2026 08
Dementia drug CervoMed readies 2026 trials on six‑month cash runway - Stock Titan ue, 17 Mar 2026 07

Insider Transactions

Filed Date	Insider	Relationship	Transaction	Shares	Price	Value
2025-11-18	ELDER WILLIAM ROBERT	General Counsel	—	3,500	$8.32	$29,250
2025-11-18	WINTON MATTHEW	Officer	—	5,000	$7.95	$41,430
2025-11-17	ALAM JOHN J	Chief Executive Officer	—	21,600	$8.46	$182,736
2025-11-17	GREGOIRE SYLVIE L	Director and Beneficial Owner of more than 10% of a Class of Security	—	21,600	$8.46	$182,736
2025-11-14	WINTON MATTHEW	Officer	—	10,000	$7.57	$75,700
2025-11-14	ALAM JOHN J	Chief Executive Officer	—	7,847	$7.51	$59,101
2025-11-14	GREGOIRE SYLVIE L	Director and Beneficial Owner of more than 10% of a Class of Security	—	7,847	$7.51	$59,101
2025-11-12	ELDER WILLIAM ROBERT	General Counsel	—	3,500	$7.44	$26,040
2025-11-12	ALAM JOHN J	Chief Executive Officer	—	5,553	$7.35	$40,815
2025-11-12	GREGOIRE SYLVIE L	Director and Beneficial Owner of more than 10% of a Class of Security	—	5,553	$7.35	$40,815

Financials

Statement View

Line Item	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	0.00	0.00	0.00	0.00
Operating Revenue	0.00	0.00	0.00	0.00
Operating Expense	28.29 +55.23%	18.23 +133.30%	7.81 +124.80%	3.48
Research And Development	21.82 +16.06%	18.80 +122.77%	8.44 +531.40%	1.34
Selling General And Administration	10.48 +14.37%	9.17 +40.61%	6.52 +204.77%	2.14
General And Administrative Expense	10.48 +14.37%	9.17 +40.61%	6.52 +204.77%	2.14
Other Gand A	10.48 +14.37%	9.17 +40.61%	6.52 +204.77%	2.14
Other Operating Expenses	-4.01 +58.86%	-9.74 -36.29%	-7.14	—
Total Expenses	28.29 +55.23%	18.23 +133.30%	7.81 +124.80%	3.48
Operating Income	-28.29 -55.23%	-18.23 -133.30%	-7.81 -124.80%	-3.48
Total Operating Income As Reported	-28.29 -55.23%	-18.23 -133.30%	-7.81 -124.80%	-3.48
EBITDA	-28.29 -55.23%	-18.23 -133.30%	-7.81 -34.65%	-5.80
Normalized EBITDA	-28.29 -55.23%	-18.23 -133.30%	-7.81 -34.65%	-5.80
Reconciled Depreciation	—	—	—	0.00
EBIT	-28.29 -55.23%	-18.23 -133.30%	-7.81 -34.65%	-5.80
Total Unusual Items	—	—	—	0.00
Total Unusual Items Excluding Goodwill	—	—	—	0.00
Special Income Charges	—	—	—	0.00
Impairment Of Capital Assets	—	—	—	0.00
Net Income	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Pretax Income	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Net Non Operating Interest Income Expense	1.34 -31.00%	1.94 +782.94%	0.22 +255.99%	0.06
Interest Expense Non Operating	—	—	0.00 -100.00%	0.00
Net Interest Income	1.34 -31.00%	1.94 +782.94%	0.22 +255.99%	0.06
Interest Expense	—	—	0.00 -100.00%	0.00
Interest Income Non Operating	1.34 -31.00%	1.94 +782.94%	0.22 +252.63%	0.06
Interest Income	1.34 -31.00%	1.94 +782.94%	0.22 +252.63%	0.06
Other Income Expense	-0.01 -740.26%	-0.00 -100.02%	5.42 +326.93%	-2.39
Other Non Operating Income Expenses	-0.01 -740.26%	-0.00 -100.02%	5.42 +326.93%	-2.39
Tax Provision	—	—	—	0.00
Tax Rate For Calcs	0.00	0.00	0.00	0.00
Tax Effect Of Unusual Items	0.00	0.00	0.00	0.00
Net Income Including Noncontrolling Interests	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Net Income From Continuing Operation Net Minority Interest	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Net Income From Continuing And Discontinued Operation	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Net Income Continuous Operations	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Normalized Income	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Net Income Common Stockholders	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Otherunder Preferred Stock Dividend	—	—	—	—
Diluted EPS	-2.98 -47.52%	-2.02 -146.34%	-0.82 +92.68%	-11.20
Basic EPS	-2.98 -47.52%	-2.02 -146.34%	-0.82 +92.68%	-11.20
Basic Average Shares	9.04 +12.00%	8.07 +203.34%	2.66 +413.65%	0.52
Diluted Average Shares	9.04 +12.00%	8.07 +203.34%	2.66 +413.65%	0.52
Diluted NI Availto Com Stockholders	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Depreciation Amortization Depletion Income Statement	—	—	—	0.00
Depreciation And Amortization In Income Statement	—	—	—	0.00
Depreciation Income Statement	—	—	—	0.00

Line Item	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Assets	22.88 -46.89%	43.08 +332.00%	9.97 +139.86%	4.16
Current Assets	22.88 -46.89%	43.08 +332.34%	9.96 +139.67%	4.16
Cash Cash Equivalents And Short Term Investments	20.86 -46.39%	38.92 +399.46%	7.79 +90.37%	4.09
Cash And Cash Equivalents	8.24 -8.49%	9.00 +15.48%	7.79 +90.37%	4.09
Cash Equivalents	—	—	7.79 +90.37%	4.09
Cash Financial	—	—	—	1.59
Other Short Term Investments	12.63 -57.79%	29.92	0.00 -100.00%	12.41
Receivables	0.43 -81.06%	2.25 +146.26%	0.92	0.00
Other Receivables	0.43 -81.06%	2.25 +146.26%	0.92	—
Prepaid Assets	1.27 -33.50%	1.91 +51.64%	1.26 +1859.39%	0.06
Current Deferred Assets	0.32	0.00	—	—
Other Current Assets	—	—	—	0.11
Total Non Current Assets	0.00	0.00 -100.00%	0.01	0.00
Net PPE	—	—	—	—
Gross PPE	—	—	—	—
Goodwill And Other Intangible Assets	—	—	—	—
Other Non Current Assets	—	—	0.01	—
Total Liabilities Net Minority Interest	4.66 +20.03%	3.88 +49.45%	2.60 -93.07%	37.44
Current Liabilities	4.66 +20.03%	3.88 +49.45%	2.60 -80.27%	13.16
Payables And Accrued Expenses	3.51 +18.61%	2.96 +99.87%	1.48 +292.34%	0.38
Payables	1.49 -3.69%	1.55 +98.22%	0.78 +704.64%	0.10
Accounts Payable	1.45 -3.79%	1.51 +128.15%	0.66 +580.84%	0.10
Current Accrued Expenses	2.02 +43.18%	1.41 +101.73%	0.70 +149.16%	0.28
Pensionand Other Post Retirement Benefit Plans Current	1.06 +32.19%	0.80 -21.72%	1.03 +181.83%	0.36
Total Tax Payable	0.04 +0.00%	0.04 -66.41%	0.12	0.00
Current Debt And Capital Lease Obligation	—	—	—	12.41
Current Debt	—	—	—	12.41
Other Current Borrowings	—	—	—	12.41
Current Capital Lease Obligation	—	—	—	—
Other Current Liabilities	0.08 -28.05%	0.12 +30.71%	0.09 -31.72%	0.13
Total Non Current Liabilities Net Minority Interest	0.00	0.00	0.00 -100.00%	24.29
Long Term Debt And Capital Lease Obligation	—	—	—	—
Long Term Capital Lease Obligation	—	—	—	—
Non Current Deferred Liabilities	—	—	—	—
Non Current Deferred Taxes Liabilities	—	—	—	—
Preferred Securities Outside Stock Equity	—	—	0.00 -100.00%	24.29
Stockholders Equity	18.22 -53.52%	39.20 +431.43%	7.38 +122.16%	-33.29
Common Stock Equity	—	—	—	-33.29
Capital Stock	0.01 +6.32%	0.01 +53.37%	0.01 +995.37%	0.00
Common Stock	0.01 +6.32%	0.01 +53.37%	0.01 +995.37%	0.00
Preferred Stock	0.00	0.00	0.00	—
Share Issued	9.25 +6.32%	8.70 +53.36%	5.67 +317.33%	1.36
Ordinary Shares Number	9.25 +6.32%	8.70 +53.36%	5.67 +317.33%	1.36
Additional Paid In Capital	115.91 +5.49%	109.87 +77.75%	61.81 +225.61%	18.98
Retained Earnings	-97.70 -38.12%	-70.73 -29.92%	-54.44 -4.16%	-52.27
Gains Losses Not Affecting Retained Earnings	0.01 -89.65%	0.06	0.00 +100.00%	-0.04
Other Equity Adjustments	0.01 -89.65%	0.06	—	-0.04
Total Equity Gross Minority Interest	18.22 -53.52%	39.20 +431.43%	7.38 +122.16%	-33.29
Total Capitalization	18.22 -53.52%	39.20 +431.43%	7.38 +122.16%	-33.29
Working Capital	18.22 -53.52%	39.20 +431.99%	7.37 +181.90%	-9.00
Invested Capital	18.22 -53.52%	39.20 +431.43%	7.38 +135.34%	-20.87
Total Debt	—	—	—	12.41
Net Debt	—	—	—	8.32
Capital Lease Obligations	—	—	—	—
Net Tangible Assets	18.22 -53.52%	39.20 +431.43%	7.38 +122.16%	-33.29
Tangible Book Value	18.22 -53.52%	39.20 +431.43%	7.38 +122.16%	-33.29

Line Item	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Cash Flow	-23.45 -41.86%	-16.53 -121.89%	-7.45 -189.57%	-2.57
Cash Flow From Continuing Operating Activities	-23.45 -41.86%	-16.53 -121.89%	-7.45 -189.57%	-2.57
Net Income From Continuing Operations	-26.97 -65.53%	-16.29 -650.08%	-2.17 +62.57%	-5.80
Depreciation Amortization Depletion	—	—	—	0.00
Depreciation	—	—	—	—
Depreciation And Amortization	—	—	—	0.00
Pension And Employee Benefit Expense	—	—	0.00 -100.00%	0.13
Stock Based Compensation	1.45 +3.05%	1.41 +244.85%	0.41 +22.11%	0.33
Deferred Tax	—	—	—	0.00
Deferred Income Tax	—	—	—	0.00
Operating Gains Losses	—	—	—	0.13
Unrealized Gain Loss On Investment Securities	—	0.00 +100.00%	-5.42 -327.05%	2.39
Gain Loss On Sale Of PPE	—	—	—	0.00
Change In Working Capital	2.92 +763.07%	-0.44 -68.60%	-0.26 -168.79%	0.38
Change In Receivables	1.83 +236.48%	-1.34 -46.26%	-0.92	0.00
Change In Prepaid Assets	0.64 +199.57%	-0.64 +46.58%	-1.20 -1510.21%	0.09
Change In Payables And Accrued Expense	0.77 -50.18%	1.54 -16.98%	1.85 +528.90%	0.29
Change In Accrued Expense	0.83 +20.84%	0.69 -46.45%	1.29 +497.66%	0.22
Change In Payable	-0.07 -107.93%	0.85 +50.22%	0.57 +614.01%	0.08
Change In Account Payable	-0.07 -107.93%	0.85 +50.22%	0.57 +614.01%	0.08
Change In Other Working Capital	-0.31	—	—	—
Investing Cash Flow	18.10 +163.14%	-28.66	0.00 +100.00%	-12.24
Cash Flow From Continuing Investing Activities	18.10 +163.14%	-28.66	0.00 +100.00%	-12.24
Net PPE Purchase And Sale	—	—	—	0.00
Sale Of PPE	—	—	—	0.00
Net Investment Purchase And Sale	18.10 +163.14%	-28.66	0.00 +100.00%	-12.24
Purchase Of Investment	-25.40 +47.19%	-48.10	0.00 +100.00%	-37.99
Sale Of Investment	43.50 +123.77%	19.44	0.00 -100.00%	25.75
Financing Cash Flow	4.59 -90.11%	46.40 +316.16%	11.15	0.00
Cash Flow From Continuing Financing Activities	4.59 -90.11%	46.40 +316.16%	11.15	0.00
Net Common Stock Issuance	4.59 -90.11%	46.40 +5628.22%	0.81	0.00
Proceeds From Stock Option Exercised	—	—	—	0.00
Net Other Financing Charges	—	—	10.34	—
Changes In Cash	-0.76 -163.32%	1.21 -67.38%	3.70 +243.79%	-2.57
Beginning Cash Position	9.00 +15.48%	7.79 +90.37%	4.09 -38.59%	6.67
End Cash Position	8.24 -8.49%	9.00 +15.48%	7.79 +90.37%	4.09
Free Cash Flow	-23.45 -41.86%	-16.53 -121.89%	-7.45 -189.57%	-2.57
Amortization Of Securities	-0.85 +29.13%	-1.21	0.00 +100.00%	-0.21
Common Stock Issuance	4.59 -90.11%	46.40 +5628.22%	0.81	0.00
Issuance Of Capital Stock	4.59 -90.11%	46.40 +5628.22%	0.81	0.00
Net Preferred Stock Issuance	—	—	—	0.01
Preferred Stock Issuance	—	—	—	0.01

SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

8-K2026-04-22 View
8-K2026-04-07 View
8-K2026-03-23 View
8-K2026-03-19 View
8-K2026-03-17 View
10-K2026-03-13 View
8-K2026-03-04 View
8-K2026-02-18 View
42026-02-13 View
42026-02-13 View
42026-02-13 View
42026-02-13 View
42026-02-13 View
42026-02-13 View
8-K2026-01-08 View
42025-12-05 View
8-K2025-12-05 View
42025-11-19 View
42025-11-19 View
42025-11-19 View

Trades

Date	User	Broker	Pattern	Type	Position Size	Entry Price	Trade P&L	Status

Posts

Published	Title	Author	Category

Headers
`Ctrl`+`Alt`+`1`	Heading 1
`Ctrl`+`Alt`+`2`	Heading 2
`Ctrl`+`Alt`+`3`	Heading 3
Formatting
`Ctrl`+`B`	Bold
`Ctrl`+`I`	Italic
`Ctrl`+`U`	Underline
`Ctrl`+`Z`	Undo
`Ctrl`+`Shift`+`Z`	Redo
`Ctrl`+`K`	Add link
`Tab`	Indent list
`Shift`+`Tab`	Outdent list